GleamWall
中文EN

LFVN Lifevantage Corp

Pharmaceutical Preparations · Nasdaq · SEC CIK 849146 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY-24.8%
TTM net income YoY-73.1%
TTM EPS YoY-73.1%
Revenue 3-yr CAGR-6.9%
Net income 3-yr CAGR2.1%

Margins

Gross margin76.5%
Operating margin2.1%
Net margin1.6%
FCF margin5.1%
EBITDA margin3.8%

Returns

ROE8.2%
ROA4.5%
ROIC (approx.)14.0%
Asset turnover2.85x

Leverage & solvency

Liabilities / assets43.8%
Debt / equity0.00x
Current ratio1.91x
Interest coverage—

Cash quality & payout

Operating cash flow / net income4.81x
Accruals ratio-17.2%
Payout ratio88.2%
Capex / revenue2.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2027Q12026-09-302026Q4*2026-06-302026Q32026-03-312026Q22025-12-312026Q12025-09-302025Q4*2025-06-302025Q32025-03-312025Q22024-12-31
Income statement
Revenue$37.12M$42.38M$43.72M$48.93M$47.56M$55.11M$58.44M$67.76M
Cost of revenue$9.15M$9.33M$9.17M$12.72M$9.74M$11.06M$11.11M$13.20M
Gross profit$27.97M$33.04M$34.54M$36.21M$37.82M$44.05M$47.33M$54.57M
R&D expense$200,000$200,000$200,000$200,000$300,000$400,000$400,000$200,000
SG&A expense$12.72M$13.87M$13.87M$15.83M$14.85M$18.68M$17.07M$18.61M
Operating income-$136,000$1.67M$1.68M$487,000$2.27M$2.15M$4.05M$3.43M
Interest expense$10,000———$10,000———
Pretax income-$184,000$1.70M$1.66M$473,000$2.24M$2.40M$4.18M$3.09M
Income tax$12,000$417,000$294,000$197,000$86,000$437,000$710,000$539,000
Net income-$196,000$1.28M$1.36M$276,000$2.15M$1.96M$3.47M$2.55M
EBITDA$594,000$2.36M$2.39M$1.24M$2.88M$2.90M$4.86M$4.23M
EPS (basic)-0.02—0.110.020.17—0.280.21
EPS (diluted)-0.02—0.110.020.17—0.260.19
Dividends declared per share—0.050.040.040.040.040.040.04
Weighted avg. shares (diluted)12.46M—12.66M12.74M12.95M—13.30M13.18M
Balance sheet
Cash & equivalents$13.73M$14.92M$12.48M$10.18M$13.09M$20.20M$22.47M$21.59M
Receivables$1.81M$2.99M$2.42M$2.26M$2.42M$3.29M$3.24M$2.09M
Inventory$14.23M$16.17M$18.38M$18.98M$20.59M$20.67M$22.22M$17.47M
Current assets$34.55M$38.30M$39.31M$38.56M$45.05M$50.89M$54.11M$45.79M
PP&E, net$8.06M$7.31M$6.85M$6.43M$6.00M$6.21M$6.73M$7.14M
Goodwill$465,000$465,000$472,000$472,000—$0——
Intangibles$2.93M$3.06M$3.19M$3.32M$245,000$245,000$224,000$257,000
Total assets$59.20M$62.11M$62.13M$61.17M$61.58M$71.96M$77.24M$68.53M
Current liabilities$18.09M$20.23M$20.10M$19.01M$18.83M$27.22M$32.58M$27.55M
Total liabilities$25.95M$28.52M$28.79M$28.18M$28.42M$37.32M$43.23M$38.64M
Shareholders' equity$33.26M$33.59M$33.34M$32.99M$33.16M$34.64M$34.01M$29.89M
Shares outstanding12.59M12.52M12.61M12.79M12.69M12.43M12.58M12.55M
Cash flow statement
Operating cash flow$533,000$4.77M$4.99M$2.79M-$2.31M$1.03M$2.23M$9.20M
Capital expenditure$1.24M$1.04M$1.01M$1.08M$439,000$199,000$331,000$492,000
Free cash flow-$707,000$3.73M$3.98M$1.71M-$2.74M$835,000$1.90M$8.71M
Investing cash flow-$1.24M-$1.04M-$1.01M-$4.83M-$439,000-$199,000-$331,000-$492,000
Financing cash flow-$603,000-$1.15M-$1.60M-$738,000-$4.30M-$3.24M-$1.13M-$1.40M
Depreciation & amortization$730,000$697,000$714,000$752,000$610,000$750,000$803,000$806,000
Stock-based compensation$306,000$263,000$700,000$600,000$826,000$1.54M$1.50M$1.70M
Dividends paid$628,000$625,000$573,000$575,000$571,000$562,000$503,000$502,000
Share buybacks$0$460,000$1.01M-$1,000$578,000$2.03M$0$0

Free plan shows the latest 8 periods; Pro shows all 65 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.